Cutler Group’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Cutler Group’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-55	Closed	-$2K	–	6469
2020 Q4	$2K	Buy	+55	New	+$7.66K	﹤0.01%	4288

Other funds holding TCON

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Cutler Group's TCON Position: Q1 2024 in Review

Cutler Group sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2024, closing a stake of 60 shares.

Cutler Group first reported a position in TCON in Q1 2021 and held it in 12 quarters. The position peaked at $44K in Q4 2021. 29 funds tracked by Wall St. Rank hold TCON as of Q1 2024.

Cutler Group reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 60 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2024.
Cutler Group first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 12 quarters.
Cutler Group's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $44K in Q4 2021.
29 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.